Faculty Profiles - NAGAO Shoji

MISC - NAGAO Shoji

Division display >> ／ All the affair displays 1 - 131 of about 131

cadaver surgical training(CST)による広汎子宮全摘出術の成績向上への試み

入江恭平, 入江恭平, 長尾昌二, 亀岡俊也, 小見山高明, 増山寿, 川口綾乃

日本解剖学会総会・全国学術集会抄録集(CD-ROM) 129th 2024

A retrospective study on the prognosis of intermediate-risk cervical cancer after radical hysterectomy

HARAGA Junko, SHIRAKAWA Shinsuke, IRIE Kyohei, IDA Naoyuki, OKAMOTO Kazuhiro, MATSUOKA Hirofumi, KUBO Kotaro, OGAWA Chikako, KAMADA Yasuhiko, NAKAMURA Keiichiro, NAGAO Shoji, MASUYAMA Hisashi

日本産科婦人科学会雑誌 75 2023

A randomized phase 3 trial of intraperitoneal versus intravenous carboplatin with dose-dense weekly paclitaxel in patients with ovarian, fallopian tube, or primary peritoneal carcinoma (a GOTIC-001/JGOG-3019/GCIG, iPocc Trial)

Keiichi Fujiwara, Shoji Nagao, Kouji Yamamoto, Hiroshi Tanabe, Aikou Okamoto, Kazuhiro Takehara, Motoaki Saito, Hiroyuki Fujiwara, David Tan, Sosuke Adachi, Satoshi Yamaguchi, Akira Kikuchi, Takeshi Hirasawa, Takeshi Yokoi, Tomonori Nagai, Toyomi Satoh, Shoji Kamiura, Akira Fujishita, Takeshi Hirasawa, Takeshi Yokoi, Tomonori Nagai, Toyomi Satoh, Shoji Kamiura, Akira Fujishita, Karen Chan, Peter Sykes, Alexander Olawaiye, Sang-Young Ryu, Wai Loong Wong, Takashi Matsumoto, Kosei Hasegawa, Takayuki Enomoto

GYNECOLOGIC ONCOLOGY 166 S49 - S50 2022.8

プラチナ製剤感受性の日本人再発卵巣癌患者を対象としたニラパリブの第II相臨床試験の最終結果(The Final Results of a Phase 2 Study of Niraparib in Japanese Patients with Platinum-Sensitive Recurrent Ovarian Cancer)

竹島信宏, 安岡稔晃, 濱西潤三, 長谷川幸清, 松浦基樹, 三浦清徳, 長尾昌二, 中井英勝, 田中尚武, 徳永英樹, 牛嶋公生, 渡利英道, 横山良仁, 加瀬陽一, 角野修司, Suri Ajit, 板持広明, 竹原和宏

日本婦人科腫瘍学会学術講演会プログラム・抄録集 64回 192 - 192 2022.7

がん治療におけるバイオマーカーのnew era Small RNAプロファイルに基づく高異型度漿液性卵巣癌プラチナ感受性の再定義

鈴木一弘, 横井暁, 吉田康将, 北川雅美, 吉原雅人, 玉内学志, 池田芳紀, 芳川修久, 須藤保, 長尾昌二, 山口聡, 梶山広明

日本婦人科腫瘍学会学術講演会プログラム・抄録集 64回 112 - 112 2022.7

原発性腹膜癌と悪性リンパ腫との鑑別に腹腔鏡下組織生検が有用であった1例

成田萌, 北井美穂, 鈴木一弘, 中澤浩志, 澁谷剛志, 山本香澄, 矢野紘子, 長尾昌二, 山口聡

産婦人科の実際 70 ( 13 ) 1625 - 1631 2021.12

Language：Japanese Publisher：金原出版(株)

＜文献概要＞症例は急速に増悪する腹部膨満症状を認めた49歳。癌性腹膜炎に類似した所見を認めるも確定診断が得られず,腹腔鏡下組織生検を行い悪性リンパ腫と診断した。リンパ腫細胞が腹膜や大網に広く浸潤した病態である腹膜リンパ腫症は稀な疾患だが,腹水や腹膜・大網播種など癌性腹膜炎によく似た所見を示すため,両者の鑑別は困難である。腹膜リンパ腫症を伴う悪性リンパ腫は侵攻性で予後不良であることが多く,早期診断と治療介入が非常に重要であり,本症例では侵襲の少ない腹腔鏡手術により早期診断ができたため報告する。

researchmap

【図解分子メカニズムから理解する婦人科がんの薬物療法】卵巣悪性腫瘍上皮性卵巣癌 e.プラチナ不応性,プラチナ抵抗性再発,late lineでの化学療法

長尾昌二

産婦人科の実際 70 ( 12 ) 1466 - 1471 2021.11

診療進行再発卵巣癌に対するレジメン選択三海婦人科癌スタディグループ(SGSG)アンケート調査結果

澁谷剛志, 長尾昌二, 佐藤慎也, 竹原和宏, 宇佐美知香, 中村圭一郎, 古宇家正, 末岡幸太郎, 紀川純三

産婦人科の実際 70 ( 10 ) 1105 - 1108 2021.10

Language：Japanese Publisher：金原出版(株)

＜文献概要＞目的:進行卵巣癌に対するレジメン選択は,ベバシズマブ(BEV)の使用を含め施設間で異なっている可能性がある。われわれはわが国におけるレジメン選択の現状を把握することを目的とし,三海婦人科癌スタディグループ(SGSG)参加施設へアンケート調査を実施した。方法:2019年9月にSGSG参加施設35施設に対して,初回術後治療,術前化学療法(NAC),インターバル腫瘍減量手術(IDS)後,プラチナ感受性再発,のそれぞれのタイミングで第一選択として使用するレジメンをアンケート形式で調査した。成績:全35施設中20施設から回答があった。初回術後治療としてTC+BEV療法を第一選択としている施設は15施設(75%)であった。プラチナ感受性再発に対してBEV併用レジメンを第一選択としている施設は17施設(85%)であった。NACにおける第一選択のレジメンはTC療法が8施設(40%),dose-dense TC療法が6施設(30%),TC+BEV療法が6施設(30%)であった。IDS後にレジメンを変更している施設が8施設(40%)あった。結論:初回治療とプラチナ感受性再発に対してBEV併用レジメンを使用している施設が多く,NACの治療方針は多様であった。

researchmap

高用量黄体ホルモン療法によって長期生存をなしえている子宮体癌4B期の1例

中澤浩志, 長尾昌二, 成田萌, 鈴木一弘, 澁谷剛志, 自見倫敦, 矢野紘子, 北井美穂, 塩崎隆也, 山口聡

日本女性医学学会雑誌 29 ( 1 ) 164 - 164 2021.10

進行上皮性卵巣癌における主治療前化学療法および腫瘍減量手術の適用(GOTIC019試験)

長尾昌二, 田村惇, 澁谷剛志, 三輪真唯子, 加藤友康, 佐藤豊実, 竹井裕二, 紙谷菜津子, 井上直樹, 中村和人, 井上彩, 藤原恵一, 鈴木光明

日本癌治療学会学術集会抄録集 59回 O8 - 1 2021.10

新規卵巣明細胞癌特異的腫瘍マーカーTFPI2の開発

宮城悦子, 荒川憲昭, 坂巻顕太郎, ルイズ横田奈朋, 山田有紀, 山口聡, 長尾昌二, 平嶋泰之, 笠松由佳, 加藤久盛, 最上多恵, 宮城洋平, 小林浩

日本癌治療学会学術集会抄録集 59回 O7 - 4 2021.10

血清中マイクロRNA解析による卵巣がん及び良性腫瘍診断マーカーの開発

若尾摂, 須藤裕子, 山本香澄, 須藤保, 長尾昌二

日本癌治療学会学術集会抄録集 59回 O7 - 6 2021.10

診療子宮頸癌に対する術後補助放射線治療による水腎症の検討

矢野紘子, 長尾昌二, 山口聡

産婦人科の実際 70 ( 8 ) 887 - 891 2021.8

Language：Japanese Publisher：金原出版(株)

＜文献概要＞当院で子宮頸癌に対する広汎子宮全摘術後に補助放射線治療を行った81例において,放射線治療が要因と思われる水腎症を8例(約10%)に認めた。半数は一過性の水腎症で自然軽快したものの,残りの半数は進行性持続性となっている。広汎子宮全摘術後早期に水腎症を認めなくてもその後の放射線治療により水腎症を発症し,腎機能を保持するために侵襲的な処置を要する場合があり,放射線治療中や治療後の注意深い腎臓評価が必要である。

researchmap

Other Link： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2021&ichushi_jid=J00535&link_issn=&doc_id=20210823220016&doc_link_id=10.18888%2Fsp.0000001816&url=https%3A%2F%2Fdoi.org%2F10.18888%2Fsp.0000001816&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

再発時にペムブロリズマブが著効した子宮体部脱分化癌の1例

山本香澄, 梶本和義, 長尾昌二, 山口聡

産婦人科の実際 70 ( 7 ) 793 - 798 2021.7

Language：Japanese Publisher：金原出版(株)

＜文献概要＞症例は53歳,主訴は不正性器出血。子宮内膜組織診は類内膜腺癌Grade 2,骨盤部MRIでは子宮体部に結節状腫瘤を認めた。子宮体癌IA期の術前診断で腹腔鏡下単純子宮全摘,両側付属器切除術を実施。術後の病理組織診断はpT1a,脱分化癌,高度のリンパ管侵襲を認めた。術後補助化学療法はTC療法を実施したが,8ヵ月後肺門部リンパ節,肺転移をきたした。TC療法を再開したが効果なく,MSI-Highを確認しペムブロリズマブを開始。2サイクル後軽度増悪傾向を示したが4サイクル後に縮小に転じ,以後奏効を維持している。

researchmap

Other Link： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2021&ichushi_jid=J00535&link_issn=&doc_id=20210727070022&doc_link_id=10.18888%2Fsp.0000001792&url=https%3A%2F%2Fdoi.org%2F10.18888%2Fsp.0000001792&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

Olaparib維持療法後のプラチナ製剤再投与の奏効率

中澤浩志, 長尾昌二, 成田萌, 鈴木一弘, 澁谷剛志, 自見倫敦, 矢野紘子, 北井美穂, 塩崎隆也, 山口聡

産婦人科の進歩 73 ( 2 ) 146 - 146 2021.5

癌腹膜播種治療のガイドライン大量癌性腹水に対する治療戦略

松崎圭祐, 有留邦明, 江本成伸, 梶本広明, 北山丈二, 高垣伸匡, 高橋孝郎, 鍔本浩志, 長尾昌二, 渡邊昭博

日本外科系連合学会誌 46 ( 3 ) 317 - 317 2021.5

早期子宮体癌に対する腹腔鏡下手術後の再発についての検討

成田萌, 北井美穂, 鈴木一弘, 中澤浩志, 澁谷剛志, 山本香澄, 自見倫敦, 矢野紘子, 塩崎隆也, 松岡和子, 長尾昌二, 山口聡

産婦人科の進歩 73 ( 2 ) 149 - 149 2021.5

HPV関連子宮頸部腫瘍に罹患した患者はHPVワクチンのインフルエンサーになり得るか

北井美穂, 成田萌, 鈴木一弘, 中澤浩志, 澁谷剛志, 山本香澄, 自見倫敦, 矢野紘子, 塩崎隆也, 松岡和子, 長尾昌二, 山口聡

日本産科婦人科学会雑誌 73 ( 臨増 ) S - 391 2021.3

当院におけるMSI-High固形癌に対するペムブロリズマブ投与の現状

成田萌, 長尾昌二, 鈴木一弘, 中澤浩志, 澁谷剛志, 山本香澄, 自見倫敦, 矢野紘子, 北井美穂, 塩崎隆也, 松岡和子, 山口聡

日本婦人科腫瘍学会雑誌 39 ( 1 ) 313 - 313 2021.1

進行卵巣癌に対するコンパニオン診断としてのBRCA遺伝学的検査の当院での現状

中澤浩志, 長尾昌二, 成田萌, 鈴木一弘, 澁谷剛志, 山本香澄, 自見倫敦, 矢野紘子, 北井美穂, 塩崎隆也, 松岡和子, 山口聡

日本婦人科腫瘍学会雑誌 39 ( 1 ) 397 - 397 2021.1

進行・再発婦人科癌に対する腹水濾過濃縮再静注法施行時のQOL評価前向きコホート研究

山本香澄, 長尾昌二, 成田萌, 鈴木一弘, 中澤浩志, 澁谷剛志, 自見倫敦, 矢野紘子, 北井美穂, 塩崎隆也, 松岡和子, 山口聡

日本婦人科腫瘍学会雑誌 39 ( 1 ) 315 - 315 2021.1

子宮頸がんに対する術後補助放射線治療による水腎症の検討

矢野紘子, 長尾昌二, 成田萌, 鈴木一弘, 中澤浩志, 澁谷剛志, 山本香澄, 自見倫敦, 北井美穂, 塩崎隆也, 松岡和子, 山口聡

日本婦人科腫瘍学会雑誌 39 ( 1 ) 348 - 348 2021.1

遠隔転移を伴う進行子宮頸癌の予後因子および治療戦略

北井美穂, 岡本葉留子, 成田萌, 鈴木一弘, 中澤浩志, 澁谷剛志, 山本香澄, 自見倫敦, 矢野紘子, 塩崎隆也, 松岡和子, 長尾昌二, 山口聡

日本婦人科腫瘍学会雑誌 39 ( 1 ) 279 - 279 2021.1

進行再発卵巣癌に対するレジメン選択三海婦人科癌スタディグループ(SGSG)アンケート調査結果

澁谷剛志, 長尾昌二, 佐藤慎也, 竹原和宏, 本郷淳司, 宇佐美知香, 中村圭一郎, 大亀真一, 依光正枝, 古宇家正, 中村紘子, 平林啓, 白山裕子, 金森康展, 末岡幸太郎, 石橋朋佳, 西村正人, 金西賢治, 中村隆文, 漆川敬治, 長治誠, 入江隆, 紀川純三

日本婦人科腫瘍学会雑誌 39 ( 1 ) 396 - 396 2021.1

術前化学療法によって硬化性苔癬が肉眼的に明らかになった外陰癌の一例

中澤浩志, 長尾昌二, 折出唯志, 成田萌, 鈴木一弘, 澁谷剛志, 山本香澄, 自見倫敦, 矢野紘子, 北井美穂, 塩崎隆也, 松岡和子, 山口聡

日本女性医学学会雑誌 28 ( 1 ) 139 - 139 2020.10

再発卵巣癌の維持療法に対するniraparibの国内単群試験投与初期の安全性評価を中心に

松元隆, 竹原和宏, 竹島信宏, 濱西潤三, 長谷川幸清, 松浦基樹, 三浦清徳, 長尾昌二, 中井英勝, 田中尚武, 徳永英樹, 牛嶋公生, 渡利英道, 横山良仁, 加瀬陽一, 角野修司, Suri Ajit, 板持広明, Niraparib-2001

日本産科婦人科学会雑誌 72 ( 臨増 ) S - 398 2020.3

再発卵巣癌の維持療法に対するniraparibの国内単群試験投与初期の安全性評価を中心に

日本産科婦人科学会雑誌 72 ( 臨増 ) S - 398 2020.3

Avelumab in platinum-resistant/refractory ovarian cancer (PRROC): phase 3 results from JAVELIN Ovarian 200

Kan Yonemori, Takashi Matsumoto, Shoji Nagao, Noriyuki Katsumata, Katsutoshi Oda, Hidemichi Watari, Hideki Tokunaga, Hiroyuki Fujiwara, Harushige Yokota, Takeshi Hirasawa, Toshiaki Nakamura, Mana Aizawa, Tomoko Okubo, Keiichi Fujiwara

ANNALS OF ONCOLOGY 30 2019.10

子宮頸部腺癌に対する同時化学放射線療法に関する多施設共同調査研究

長井裕, 三上幹男, 武隈宗孝, 喜多川亮, 長尾昌二, 戸澤晃子, 西尾真, 小林栄仁, 生水真紀夫, 宮城悦子, 横田治重, 笠松由佳, 青木陽一, 岩瀬春子, 山口聡, 苛原稔, 横山正俊, 八重樫伸生, 増山寿, 竹原和宏, 中村俊昭, 青木大輔, 早瀬良二, 中村和人, 田畑務, 上浦祥司, 岩佐尚美, 平澤猛, 杉野法広, 塩沢丹里, 小林浩, 松元隆, 森重健一郎, 北正人, 板持広明, 菊池朗, 杉浦真弓, 藤原葉一郎, 徳山治, 大石徹郎, 小林裕明, 渡利英道, 水野美香, 吉田好雄, 村上文洋, 高橋慶行, 横井猛, 楢原久司, 小寺宏平, 横山良仁, 沖明典, 中西慶喜, 水之江知哉, 杉山徹

日本産科婦人科学会雑誌 71 ( 臨増 ) S - 324 2019.2

子宮頸部非扁平上皮癌の生検標本におけるp16INK4a免疫染色の術前化学療法効果予測因子としての有用性

千葉淳美, 島田宗昭, 三上芳喜, 長尾昌二, 竹島信宏, 寺本典弘, 清川貴子, 杉山徹, 紀川純三, 三海婦人科スタディーグループ

日本産科婦人科学会雑誌 71 ( 臨増 ) S - 321 2019.2

進行卵巣癌に対する術前化学療法dose dense TCとconventional TCの後方視的比較検討

澁谷剛志, 長尾昌二, 鈴木一弘, 金田倫子, 山本香澄, 自見倫敦, 矢野紘子, 北井美穂, 塩崎隆也, 松岡和子, 須藤保, 山口聡

日本産科婦人科学会雑誌 71 2019

子宮体癌卵巣転移と子宮体癌,卵巣癌同時重複癌症例の臨床病理的検討

金田倫子, 長尾昌二, 鈴木一弘, 澁谷剛志, 山本香澄, 自見倫敦, 矢野紘子, 北井美穂, 塩崎隆也, 松岡和子, 須藤保, 山口聡

日本産科婦人科学会雑誌 71 2019

婦人科癌に伴う癌性髄膜炎5症例の検討

矢野紘子, 鈴木一弘, 金田倫子, 澁谷剛志, 山本香澄, 自見倫敦, 北井美穂, 塩崎隆也, 松岡和子, 須藤保, 長尾昌二, 山口聡

日本産科婦人科学会雑誌 71 2019

癌ゲノム医療での進行上皮性卵巣癌に対する経腟超音波ガイド下針生検術の有用性

金田倫子, 長尾昌二, 鈴木一弘, 澁谷剛志, 山本香澄, 自見倫敦, 矢野紘子, 北井美穂, 塩崎隆也, 松岡和子, 須藤保, 山口聡

日本婦人科腫瘍学会雑誌 37 ( 3 ) 2019

早期卵巣癌における後腹膜リンパ節郭清の治療的意義の検討

山本香澄, 長尾昌二, 鈴木一弘, 金田倫子, 澁谷剛志, 自見倫敦, 矢野紘子, 北井美穂, 塩崎隆也, 松岡和子, 須藤保, 山口聡

日本産科婦人科学会雑誌 71 2019

Propensity score-matched analysis of systemic chemotherapy versus hysterectomy for patients with residual cervical disease after definitive radiotherapy/concurrent chemoradiotherapy

Munetaka Takekuma, Fumiaki Takahashi, Seiji Mabuchi, Wataru Kudaka, Koji Horie, Mariko Ikeda, Ayumi Shikama, Akira Mitsuhashi, Shoji Nagao, Shiro Suzuki, Mika Mizuno, Shin Nishio, Hideki Tokunaga, Yukinobu Ota, Takahiro Kasamatsu, Ryo Kitagawa, Takafumi Toita, Hiroaki Kobayashi, Mitsuya Ishikawa, Nobuo Yaegashi

JOURNAL OF CLINICAL ONCOLOGY 36 ( 15 ) 2018.5

進行上皮性卵巣癌に対する主治療前化学療法前の経腟超音波ガイド下腫瘍生検

金田倫子, 長尾昌二, 鈴木一弘, 澁谷剛志, 山本香澄, 自見倫敦, 矢野紘子, 北井美穂, 塩崎隆也, 松岡和子, 須藤保, 山口聡

日本癌治療学会学術集会(Web) 56th 2018

当院における遺伝性乳癌卵巣癌症候群(HBOC)に対する取り組み

矢野紘子, 矢野紘子, 長尾昌二, 長尾昌二, 鈴木一弘, 金田倫子, 澁谷剛志, 山本香澄, 自見倫敦, 北井美穂, 塩崎隆也, 松岡和子, 須藤保, 山口聡, 秋丸憲子, 菅原宏美, 浦川優作, 日下咲, 松本光史

産婦人科の進歩 70 ( 4 ) 2018

子宮体癌卵巣転移と子宮体部,卵巣同時重複癌症例の臨床的背景

金田倫子, 長尾昌二, 細川雅代, 鈴木一弘, 澁谷剛志, 山本香澄, 自見倫敦, 矢野紘子, 北井美穂, 塩崎隆也, 松岡和子, 須藤保, 山口聡

日本女性医学学会雑誌 26 2018

本邦での子宮頸癌患者におけるホルモン補充療法の実態調査 JGOGアンケート調査結果

西ヶ谷順子, 小林陽一, 高松潔, 武隈宗孝, 喜多川亮, 小林栄仁, 戸澤晃子, 長尾昌二, 西尾真, 三上幹男

日本女性医学学会雑誌 25 ( Suppl. ) 156 - 156 2017.10

Phase II study of perioperative combination chemotherapy with triweekly carboplatin and weekly dose dense paclitaxel and radical hysterectomy for locally advanced cervical cancer (SGSG-016 study).

Shoji Nagao, Ai Kogiku, Michiko Nonaka, Yuko Shiroyama, Tetsuro Oishi, Satoshi Yamaguchi, Kazuhiro Takehara, Muneaki Shimada, Junzo Kigawa

JOURNAL OF CLINICAL ONCOLOGY 35 2017.5

卵巣癌化学療法 : GOTIC001/JGOG3019(iPocc)試験 (特集産婦人科臨床研究最前線) -- (腫瘍領域)

長尾昌二, 藤原恵一

産科と婦人科 83 ( 10 ) 1154 - 1159 2016.10

A retrospective study of pelvic fractures after radiotherapy for cervical cancer

34 ( 4 ) 613 - 619 2016.10

P2-17-1 プラチナ製剤薬物動態に関するtriangle modelの開発(Group17 卵巣腫瘍・治療2・化学療法,一般演題,公益社団法人日本産科婦人科学会第68回学術講演会)

宮木康成, 宮木裕司, 河西邦浩, 山本順子, 藤原恵一, 紀川純三, 長尾昌二, 鍔本浩志, 小田隆司, 橋本雅, 三宅貴仁, 三宅馨

日本産科婦人科學會雜誌 68 ( 2 ) 659 - 659 2016

子宮頸癌IB2〜IIB期の最適治療を模索する術前化学療法(NAC)+手術+術後化学療法(ddTP療法)による治療戦略 SGSG013-014

山口聡, 谷岡真樹, 尾上琢磨, 佐藤慎也, 長尾昌二, 竹原和宏, 西村正人, 島田宗昭, 藤原潔, 紀川純三

日本癌治療学会誌 50 ( 3 ) 91 - 91 2015.9

子宮頸がんNAC/手術子宮頸部通常型腺癌に対する術前化学療法としてのDocetaxel/Carboplatin併用療法の有用性

小島淳美, 島田宗昭, 長尾昌二, 竹島信宏, 庄子忠宏, 須藤保, 平田英司, 竹原和宏, 金森康展, 早瀬良二, 清川貴子, 三上芳喜, 紀川純三, 西村隆一郎

日本婦人科腫瘍学会雑誌 33 ( 3 ) 536 - 536 2015.6

子宮体癌の標準的治療とは頸部浸潤を疑う子宮体癌に対する広汎子宮全摘術の必要性 GOTIC-005後方視的多施設検討

高野政志, 越智寛幸, 竹井裕二, 宮本守員, 荷見よう子, 金田佳史, 中村和人, 黒崎亮, 佐藤豊実, 藤原寛行, 長尾昌二, 古谷健一, 横田治重, 伊藤公彦, 峯岸敬, 吉川裕之, 藤原恵一, 鈴木光明

日本婦人科腫瘍学会雑誌 32 ( 3 ) 367 - 367 2014.6

Cisplatin with dose-dense paclitaxel before and after radical hysterectomy for locally advanced cervical cancer: Final results of a multicenter phase II study (Sankai Gynecology Study Group 013).

Satoshi Yamaguchi, Kiyoshi Fujiwara, Shinya Sato, Shoji Nagao, Kazuhiro Takehara, Masato Nishimura, Muneaki Shimada, Junzo Kigawa, Maki Tanioka

JOURNAL OF CLINICAL ONCOLOGY 32 ( 15 ) 2014.5

婦人科腫瘍・臨床試験進行・再発子宮頸部非扁平上皮癌に対するDC(DTX/CBDCA)療法の第II相試験(SGSG 006/Intergroup study)

島田宗昭, 庄子忠宏, 長尾昌二, 藤原恵一, 高野忠夫, 八重樫伸生, 村上明弘, 本郷淳司, 杉山徹, 紀川純三, 三海婦人科癌スタディグループ

日本産科婦人科学会雑誌 66 ( 2 ) 429 - 429 2014.2

Principle and evolving role of intraperitoneal chemotherapy in ovarian cancer International journal

Keiichi Fujiwara, Shoji Nagao, Eriko Aotani, Kosei Hasegawa

Expert Opinion on Pharmacotherapy 14 ( 13 ) 1797 - 1806 2013.9

Language：English

Introduction: Intraperitoneal (i.p.) chemotherapy has been extensively studied in the ovarian cancer field. Despite the fact that three large randomized trials that were conducted in the United States showed survival benefit, meta-analysis also showed survival benefit and the National Cancer Institute (NCI) released a clinical announcement recommending i.p. chemotherapy for optimally debulked advanced stage ovarian cancer in 2006, i.p. chemotherapy has not been widely accepted by the gynecologic oncology community, mainly because of its toxicities. Areas covered: In this review, previously available evidence, new evidence published since the NCI clinical announcement and ongoing clinical trials will be discussed. Expert opinion: Three currently ongoing randomized Phase III trials will provide extremely important information about whether a less toxic i.p. regimen using carboplatin will be beneficial for patients with advanced ovarian cancer. They are important because it may be possible to solve many of the questions or unmet needs in i.p. chemotherapy by combining these three trials. © 2013 Informa UK, Ltd.

DOI： 10.1517/14656566.2013.820705

Scopus

PubMed

researchmap

シスプラチンを含む婦人科がん化学療法の悪心・嘔吐に対する標準支持療法の検討

米田聡美, 竹島信宏, 久慈志保, 高野政志, 栗谷圭子, 甲斐健太郎, 島田宗昭, 寺尾公成, 長尾昌二, 大槻健郎, 西洋孝, 平嶋泰之, 伊藤公彦

日本癌治療学会誌 48 ( 3 ) 1303 - 1303 2013.9

Gynecologic caner

246 ( 9 ) 657 - 661 2013.8

Pathologic complete response to cisplatin with dose-dense paclitaxel as neoadjuvant chemotherapy for locally advanced cervical cancer: Preliminary results of a multicenter phase II study with additional mutation analysis of adeno/adenosquamous carcinoma

Maki Tanioka, Satoshi Yamaguchi, Shinya Sato, Shoji Nagao, Kazuhiro Takehara, Masato Nishimura, Tamotsu Sudo, Satoshi Morita, Hironobu Minami, Shunichi Negoro, Muneaki Shimada, Junzo Kigawa, Kiyoshi Fujiwara

JOURNAL OF CLINICAL ONCOLOGY 31 ( 15 ) 2013.5

「プラチナ感受性」の概念は再発子宮体癌に適用可能か?

長尾昌二, 西尾真, 岡田智志, 大槻健郎, 山口聡, 横須賀治子, 荷見よう子, 高野政志, 竹井裕二, 長谷川哲哉, 松元隆, 中村和人, 佐薙佳世, 武隈宗孝, 三浦史晴, 二神真行, 本郷淳司, 金田佳史, 鍔本浩志, 長谷川清志, 繁田直哉, 藤本英夫, 岡田真澄, 島田宗昭, 荒川敦志, 大下孝史, 伊東史学, 竹原和宏, 関口勲, 金森康展, 藤原恵一, 鈴木光明, 紀川純三

日本産科婦人科学会雑誌 65 ( 2 ) 856 - 856 2013.2

胃型形質を有する子宮頸部粘液性腺癌の抗癌剤感受性に関する検討

小島淳美, 島田宗昭, 長尾昌二, 竹島信宏, 庄子忠宏, 須藤保, 平田英司, 竹原和宏, 金森康展, 早瀬良二, 紀川純三, 西村隆一郎, 三海婦人科スタディーグループ

日本産科婦人科学会雑誌 65 ( 2 ) 712 - 712 2013.2

Neoadjuvant chemotherapy of docetaxel and carboplatin in patients with stage Ib2 to IIb nonsquamous cervix cancer of the uterus.

Shoji Nagao, Muneaki Shimada, Keiichi Fujiwara, Nobuhiro Takeshima, Ken Takizawa, Tadahiro Shoji, Toru Sugiyama, Satoshi Yamaguchi, Ryuichiro Nishimura, Junzo Kigawa

JOURNAL OF CLINICAL ONCOLOGY 30 ( 15 ) 2012.5

Neoadjuvant chemotherapy of docetaxel and carboplatin in patients with stage Ib2 to IIb nonsquamous cervix cancer of the uterus.

Shoji Nagao, Muneaki Shimada, Keiichi Fujiwara, Nobuhiro Takeshima, Ken Takizawa, Tadahiro Shoji, Toru Sugiyama, Satoshi Yamaguchi, Ryuichiro Nishimura, Junzo Kigawa

JOURNAL OF CLINICAL ONCOLOGY 30 ( 15 ) 2012.5

卵巣癌に対する腹腔内化学療法特集播種治療の展望

SURGERY FRONTIER 19 ( 2 ) 65 - 71 2012.4

Pharmacogenetic analysis of the weekly paclitaxel/IP carboplatin combination therapy for ovarian and peritoneal cancers

Hidetaka Eguchi, Norihiro Iwasa, Muneaki Shimada, Satoshi Takeuchi, Hiroyuki Fujiwara, Satoru Wada, Shoji Nagao, Mitsuaki Suzuki, Toru Sugiyama, Junzo Kigawa, Keiichi Fujiwara, Masahiko Nishiyama

CANCER RESEARCH 72 2012.4

婦人科がん最新の研究動向腹腔内化学療法

日本臨床 70 ( 4 ) 610 - 616 2012.3

Intravenous/Intraperitoneal Paclitaxel and Intraperitoneal Carboplatin in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma A Feasibility Study International journal

Shoji Nagao, Norihiro Iwasa, Akira Kurosaki, Tadaaki Nishikawa, Rie Ohishi, Kosei Hasegawa, Tomoko Goto, Keiichi Fujiwara

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 22 ( 1 ) 70 - 75 2012.1

Language：English Publisher：LIPPINCOTT WILLIAMS & WILKINS

Objective: This study aimed to evaluate intravenous (IV)/intraperitoneal (IP) paclitaxel and IP carboplatin (TCipTip therapy) feasibility in epithelial ovarian (EOC), fallopian tube (FTC), or peritoneal carcinoma (PC) patients.
Methods: From December 2007 to August 2010, 20 women with histologically confirmed stage IC to IV EOC, FTC, or PC received 6 TCipTip cycles after the primary cytoreductive surgery. Intravenous paclitaxel was administered at 135 mg/m(2) followed by IP carboplatin based on the area under the curve = 6 on day 1; IP paclitaxel at 60 mg/m2 was administered on day 8. The toxicity grade was determined by CTCAE version 3.0. The institutional review board requested we reduce the IP paclitaxel dose in the first cycle to ensure safety.
Results: Twenty women, including 18 with EOC, 1 with stage IIC FTC, and 1 with stage IV primary PC, received TCipTip therapy. There were 12 serous, 5 endometrioid, 1 mucinous, 1 clear cell adenocarcinoma, and 1 mixed carcinoma (clear cell and endometrioid) cases. Eleven women achieved optimal status at primary surgery. Grade 3/4 hematologic toxicity incidence was 73% (neutrocytopenia), 9% (thrombocytopenia), and 24% (anemia). Grade 3/4 nonhematologic toxicities were observed in 5 patients (4 with grade 3 allergy and 1 with grade 3 ileus). Twelve patients (60%) completed more than 6 chemotherapy cycles. Reasons for interruption included paclitaxel allergy, grade 2 abdominal pain, carboplatin allergy during the seventh cycle, disease progression, pleural embolism, ileus, and address change.
Conclusions: Toxicities for TCipTip therapy were acceptable; this therapy is feasible for EOC, FTC, or PC patients. Further TCipTip therapy evaluation is warranted.

DOI： 10.1097/IGC.0b013e318234f927

Web of Science

PubMed

researchmap

Phase II study of combination chemotherapy with docetaxel and carboplatin for locally advanced or recurrent cervical cancer. International journal

Shigeki Takekida, Keiichi Fujiwara, Shoji Nagao, Satoshi Yamaguchi, Nobutaka Yoshida, Fuminori Kitada, Junzo Kigawa, Naoki Terakawa, Ryuichiro Nishimura

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20 ( 9 ) 1563 - 8 2011.10

Language：English

The efficacy and toxicity of combination chemotherapy with docetaxel + carboplatin were evaluated in patients with locally advanced or recurrent cervical cancer. A total of 71 patients with cervical cancer were enrolled into this trial, and 66 patients were considered eligible. The patients were administered docetaxel at 60 mg/m2 followed by carboplatin based on area under the curve of 6, both by intravenous infusion, every 3 weeks, with the treatment repeated for 1 to 6 cycles depending on the goal of the therapy. The response was evaluated based on the Response Evaluation Criteria in Solid Tumors criteria. Toxicity to chemotherapy was evaluated according to the National Cancer Institute Common Toxicity Criteria. Of the 66 eligible patients, 62 had locally advanced cervical cancer with no history of previous treatment, whereas 4 patients had recurrent cervical cancer. A total 149 cycles of chemotherapy were administered, with a median of 2.3 cycles (range, 1-6) per patient. The overall clinical response rate was 63.7% (44/66, 95% confidence interval, 52.1-75.3). In the neoadjuvant chemotherapy setting, the overall clinical response rate was 69.3% (43/62; 43/62, 95% confidence interval, 57.8-80.8), and the response rates in patients with squamous cell carcinoma and nonsquamous cell carcinoma were 69.7% (23/33, 95% confidence interval, 54.0-85.4) and 68.9% (20/29, 95% confidence interval, 52.1-85.7), respectively. On the other hand, in patients with recurrent cervical cancer, the overall response rate was 25.0% (1/4, 95% confidence interval, -17.4 to 67.4). Nonhematological toxicities were mainly grade 1 or 2. Hematological toxicity was encountered mostly in the form of neutropenia and thrombocytopenia. Combination chemotherapy with docetaxel + carboplatin is a safe and well-tolerated treatment for patients with advanced cervical cancer and is effective against not only squamous cell carcinoma, but also adenocarcinoma.

PubMed

researchmap

腹腔内化学療法 (今月の臨床卵巣がん--最新の治療戦略) -- (初回治療--ファーストラインの化学療法)

藤原恵一, 岩佐紀宏, 長尾昌二

臨床婦人科産科 65 ( 7 ) 891 - 896 2011.7

Taxane系薬剤のIP/IV投与モデル

宮木康成, 藤原恵一, 宮木裕司, 小田隆司, 長尾昌二, 伊藤潔, 高野忠夫, 八重樫伸生, 山口万紀子, 高田智价, 清川麻知子, 堀本直幹, 橋本雅, 三宅馨

日本婦人科腫瘍学会雑誌 29 ( 3 ) 530 - 530 2011.6

Supportive care for hand-foot syndrome and stomatitis in relapsed ovarian cancer patients receiving pegylated liposomal doxorubicin.

M. Shimada, S. Sato, T. Otsuki, T. Takano, N. Yaegashi, H. Fujiwara, M. Suzuki, S. Nagao, K. Fujiwara, Y. Yokoyama, H. Mizunuma, S. Kumagai, T. Sugiyama, H. Kurachi, K. Takizawa, M. Hiura, H. Yoshikawa, K. Takehara, K. Ochiai, J. Kigawa

JOURNAL OF CLINICAL ONCOLOGY 29 ( 15 ) 2011.5

Development of a mathematical model of intraperitoneal/intravenous infusion of taxanes.

Y. Miyagi, K. Fujiwara, K. Ito, Y. Miyagi, T. Takano, S. Nagao, N. Yaegashi, T. Oda, T. Miyake, K. Miyake

JOURNAL OF CLINICAL ONCOLOGY 29 ( 15 ) 2011.5

卵巣がんの薬物療法腹腔内化学療法（IP療法）

臨床腫瘍プラクティス 2011.4

がん性腹膜炎

産科と婦人科 2011.3

A Randomized Phase II/III Trial of 3 Weekly Intraperitoneal versus Intravenous Carboplatin in Combination with Intravenous Weekly Dose-dense Paclitaxel for Newly Diagnosed Ovarian, Fallopian Tube and Primary Peritoneal Cancer International journal

Keiichi Fujiwara, Eriko Aotani, Tetsutaro Hamano, Shoji Nagao, Hiroyuki Yoshikawa, Toru Sugiyama, Junzo Kigawa, Daisuke Aoki, Noriyuki Katsumata, Masahiro Takeuchi, Mitsuaki Suzuki

JAPANESE JOURNAL OF CLINICAL ONCOLOGY 41 ( 2 ) 278 - 282 2011.2

Language：English Publisher：OXFORD UNIV PRESS

Retrospective studies and a Phase II trial demonstrated the promising efficacy and safety of intraperitoneal administration of carboplatin in ovarian, fallopian tube and primary peritoneal cancer. A Japanese Gynecologic Oncology Group 3016 randomized Phase III trial for these cancers showed dose-dense weekly administration of paclitaxel significant improvement of progression-free survival and overall survival over every 3-week administration. From June 2010, we have been conducting a randomized Phase II/III trial of intravenous versus intraperitoneal administration of carboplatin every 3 week in combination with dose-dense weekly administration of paclitaxel. The purpose of this trial is to prove the superiority of intraperitoneal administration of carboplatin over intravenous administration. Primary endpoint is progression-free survival and secondary endpoints include overall survival, quality of life assessment and cost-benefit. The first 120 patients will be evaluated for the feasibility of intraperitoneal arm and a total of 746 patients will be enrolled in a Phase III study.

DOI： 10.1093/jjco/hyq182

Web of Science

PubMed

researchmap

卵巣がんIa期および境界悪性腫瘍における妊孕能温存治療

産婦人科の実際 2011.2

再発卵巣癌に対するリポソーマルドキソルビシン単剤療法における手足症候群および口内炎予防のためのサポーティブケアに関する多施設共同研究

島田宗昭, 紀川純三, 佐藤慎也, 八重樫伸生, 高野忠夫, 大槻健郎, 鈴木光明, 藤原寛行, 藤原恵一, 長尾昌二, 水沼英樹, 横山良仁, 倉智博久, 中原健次, 杉山徹, 熊谷晴介, 滝澤憲, 岩瀬春子, 竹原和宏, 中村紘子, 日浦昌道, 白山裕子, 吉川裕之, 佐藤豊実, 落合和徳, 山田恭輔, 波多江正紀, 中村俊昭

日本産科婦人科学会雑誌 63 ( 2 ) 868 - 868 2011.2

卵巣がん1a期および境界悪性腫瘍における妊孕性温存治療 (特集婦人科がん妊孕性・卵巣機能温存治療と妊娠・分娩)

長尾昌二, 西川忠暁, 黒崎亮

産婦人科の実際 60 ( 2 ) 181 - 187 2011.2

P2-28-3 当科で行った腹腔内化学療法におけるIntraperitoneal Port System(IPS)関連合併症の検討(Group130 婦人科悪性腫瘍・その他,一般演題,第63回日本産科婦人科学会学術講演会)

大石理恵, 長尾昌二, 鈴木裕之, 佐藤加寿子, 黒崎亮, 岩佐紀宏, 長谷川幸清, 藤原恵一

日本産科婦人科學會雜誌 63 ( 2 ) 888 - 888 2011

腹腔内化学療法の現状と将来展望 (特集卵巣がんに関する最新トピックス)

長尾昌二, 祖川侑子, 水上順智

産婦人科の実際 59 ( 10 ) 1519 - 1525 2010.10

ASSESSMENT OF SUPPORTIVE CARE FOR HAND-FOOT SYNDROME AND STOMATITIS IN RELAPSED OVARIAN CANCER PATIENTS RECEIVING PEGYLATED LIPOSOMAL DOXORUBICIN

T. Otsuki, N. Yaegashi, M. Shimada, S. Nagao, M. Suzuki, H. Mizunuma, H. Kurachi, T. Sugiyama, K. Takizawa, J. Kigawa

ANNALS OF ONCOLOGY 21 388 - 389 2010.10

Single nedaplatin treatment as salvage chemotherapy for platinum/taxane-resistant/refractory epithelial ovarian, tubal and peritoneal cancers

Tomoko Goto, Masashi Takano, Rie Ohishi, Norihiro Iwasa, Motohiro Shimizu, Kosei Hasegawa, Shoji Nagao, Keiichi Fujiwara

JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH 36 ( 4 ) 764 - 768 2010.8

Language：English Publisher：WILEY-BLACKWELL PUBLISHING, INC

Aim:
To evaluate toxicity, response and progression-free survival of single nedaplatin chemotherapy in women with platinum/taxane-resistant/refractory epithelial ovarian, tubal and peritoneal cancer.
Methods:
Seventeen patients with platinum/taxane-resistant/refractory epithelial ovarian, fallopian tube or primary peritoneal cancer who were treated with a single nedaplatin regimen at 90 mg/m2 administration on day 1 of a 28-day cycle in our institution between 2005 and 2007 were retrospectively investigated.
Results:
Ten of 17 patients (59%) had measurable disease. Seven patients were evaluated according to cancer antigen (CA) 125 levels. The overall response was 24% (complete response, 2 patients; partial response, 2 patients). Two of these 4 patients had measurable disease. Stable disease and progressive disease was noted in 6 (35%) and 7 (41%) patients. Median progression-free survival was 8 months (range 3-11) in patients who responded to therapy and 4 months (range 2-6) in patients with stable disease. Mean platinum-free interval due to treatment without using platinum analogues after developing platinum-resistant/refractory disease was 11 months (range 8-12) in patients who responded to nedaplatin regimen and 3 months (range 1-11) in patients who did not (P < 0.01), whereas mean treatment-free interval was 3 months (range 1-5) in responders and 1 month (range 1-3) in non-responders, which did not show a significant difference. Grade 4 hematological toxicity was observed in 2 of 17 patients (12%). No grade 3 or 4 non-hematological toxicity occurred. All toxicities were managed on an outpatient basis.
Conclusions:
Single nedaplatin treatment for platinum/taxane-resistant/refractory ovarian, tubal and peritoneal cancer patients is the candidate of salvage chemotherapy with comparable effectiveness and less toxicity to other approved regimens.

DOI： 10.1111/j.1447-0756.2010.01217.x

Web of Science

researchmap

Single nedaplatin treatment as salvage chemotherapy for platinum/taxane-resistant/refractory epithelial ovarian, tubal and peritoneal cancers International journal

Tomoko Goto, Masashi Takano, Rie Ohishi, Norihiro Iwasa, Motohiro Shimizu, Kosei Hasegawa, Shoji Nagao, Keiichi Fujiwara

JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH 36 ( 4 ) 764 - 768 2010.8

Language：English Publisher：WILEY-BLACKWELL PUBLISHING, INC

DOI： 10.1111/j.1447-0756.2010.01217.x

Web of Science

PubMed

researchmap

Carboplatin therapy in combination with low-dose paclitaxel

IWASA Norihiro, NAGAO Shoji, OISI Rie, SHIMIZU Motohiro, HASEGAWA Kosei, FUJIWARA Keiichi

28 ( 2 ) 150 - 154 2010.4

卵巣癌と生殖機能温存治療の実際妊孕能の可能性と限界を考える

長尾昌二, 仲神宏子, 塚原沙耶, 大石理恵, 岩佐紀宏, 長谷川幸清, 藤原恵一

産婦人科の実際 2010.3

卵巣癌の手術と妊孕能温存手術

長尾昌二, 仲神宏子, 塚原沙耶, 大石理恵, 岩佐紀宏, 長谷川幸清, 藤原恵一

産婦人科治療 2010.3

オープンディスカッション卵巣がん委員会報告 iPocc試験プロトコール概要

長尾昌二

第8回婦人科悪性腫瘍化学療法研究機構年次会議（総会）記録集 158 - 61 2010.1

P1-140 子宮体部病変に対するMRI拡散強調画像を用いたADC値の有用性の検討(Group18 婦人科腫瘍画像診断1,一般演題,第62回日本産科婦人科学会学術講演会)

長谷川幸清, 大石理恵, 岩佐紀宏, 清水基弘, 長尾昌二, 藤原恵一

日本産科婦人科學會雜誌 62 ( 2 ) 395 - 395 2010

上皮性卵巣癌の妊孕性温存療法の適応と限界

長尾昌二, 岩佐紀宏, 藤原恵一

臨床婦人科産科 2009.12

Phase II Study of Intraperitoneal Carboplatin With Intravenous Paclitaxel in Patients With Suboptimal Residual Epithelial Ovarian or Primary Peritoneal Cancer A Sankai Gynecology Cancer Study Group Study International journal

Keiichi Fujiwara, Shoji Nagao, Junzo Kigawa, Jun Noma, Nobuo Akamatsu, Yasunari Miyagi, Fumitaka Numa, Makoto Okada, Eriko Aotani

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 19 ( 5 ) 834 - 837 2009.7

Language：English Publisher：LIPPINCOTT WILLIAMS & WILKINS

Purpose: To assess the antitumor efficacy and safety of 2 treatment modalities: intraperitoneal carboplatin combined with intravenous (IV) paclitaxel.
Patients and Methods: Eligible patients were those with epithelial ovarian carcinoma or primary peritoneal carcinoma stages 11 to IV who underwent initial surgery and had a residual tumor size of 2 cm or larger. Patients received IV paclitaxel 175 mg/m(2) followed by intraperitoneal carboplatin AUC6. The primary end point was a response. Secondary end points were toxicity, progression-free survival, and overall survival.
Results: Twenty-six patients were enrolled, and 24 patients were eligible for assessment. The response rate was 83.3% (95% CI, 62.6%-95.3%; Table 4). The median progression-free survival was 25 months. The median overall survival had not been reached. Incidences of grade (G) 3/4 hematological toxicities were absolute neutrophil count, 96%; hemoglobin, 29%; and thrombocytopenia, 16%. Nonhematological toxicities included G2 liver function, 4%; G3 sensory neuropathy, 8%; and G3 myalgia and arthralgia, 4%.
Conclusions: Intraperitoneal administration of carboplatin combined with IV paclitaxel was well tolerated and showed satisfactory response in the patients with bulky residual tumor. Large-scale phase III trial comparing with IV carboplatin is warranted in this patient population.

DOI： 10.1111/IGC.0b013e3181a29dfe

Web of Science

PubMed

researchmap

Keiichi Fujiwara, Shoji Nagao, Junzo Kigawa, Jun Noma, Nobuo Akamatsu, Yasunari Miyagi, Fumitaka Numa, Makoto Okada, Eriko Aotani

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 19 ( 5 ) 834 - 837 2009.7

Language：English Publisher：LIPPINCOTT WILLIAMS & WILKINS

DOI： 10.1111/IGC.0b013e3181a29dfe

Web of Science

researchmap

上皮性卵巣がんの妊孕性温存手術

長尾昌二, 大石理恵, 伊藤百合子, 岩佐紀宏, 清水基弘, 後藤友子, 藤原恵一

産科と婦人科 76 ( 4 ) 403 - 8 2009.4

卵巣境界悪性腫瘍の妊孕能温存治療 (特集妊孕能温存の婦人科がん治療)

長尾昌二, 大石理恵, 伊藤百合子

産婦人科の実際 58 ( 3 ) 375 - 381 2009.3

An estimation of total number of cycles of chemotherapy in patients with epithelial ovarian cancer worldwide

S. Nagao, R. Ohishi, N. Iwasa, M. Shimizu, T. Goto, K. Fujiwara

GYNECOLOGIC ONCOLOGY 112 ( 2 ) S56 - S57 2009.2

Is the adjustment of serum creatinine level from < 0.6 mg/dl to 0.6 mg/dl justified in estimating carboplatin clearance calculated by the Jelliffe formula?

Shoji Nagao, Rie Ohishi, Norihiro Iwasa, Motohiro Shimizu, Kosei Hasegawa, Tomoko Goto, Keiichi Fujiwara

Clinical Ovarian Cancer 2 ( 1 ) 48 - 51 2009

Language：English Publisher：Cancer Information Group, LP

In current Gynecologic Oncology Group studies, serum creatinine level is adjusted to 0.6 mg/dL in patients with levels &lt
0.6 mg/dL (Adjusted-Jelliffe formula). The purpose of this study is to evaluate whether this adjustment is suitable. Patients and Methods: Carboplatin clearance was estimated in 115 patients with serum creatinine &lt
0.6 mg/dL who received carboplatin-based chemotherapy for gynecologic malignancies between January 1996 and August 2004. The clearance was estimated using the Cockroft-Gault, Jelliffe, and Adjusted-Jelliffe formulae. The 3 estimations were then compared with each other using the post hoc Wilcoxon signed rank test. Bias was assessed by mean percentage error (MPE), and precision was assessed by mean absolute percentage error (MAPE). The relationships between body surface area (BSA) and ratios of estimated carboplatin clearance (Jelliffe formula/Cockroft-Gault formula and Adjusted-Jelliffe formula/Cockroft-Gault formula) were evaluated by simple regression analysis. Results: The carboplatin clearance calculated by the Jelliffe formula was significantly larger than the other 2 formulae (P &lt
.0001). Although MPE was reduced from +20 to +6 by adjustment of serum creatinine, MAPE was barely reduced from 21 to 14. The simple regression line represents correlation between BSA and ratios of estimated carboplatin clearance was merely translated to below by adjusting the serum creatinine level, and the bias by BSA was not corrected. Conclusion: Despite adjusting the serum creatinine level, the Adjusted-Jelliffe formula overestimates the creatinine clearance when compared with the Cockcroft-Gault formula.

DOI： 10.3816/COC.2009.n.007

Scopus

researchmap

Combination chemotherapy of intraperitoneal carboplatin and intravenous paclitaxel in suboptimally debulked epithelial ovarian cancer

S. Nagao, K. Fujiwara, R. Ohishi, Y. Nakanishi, N. Iwasa, M. Shimizu, T. Goto, K. Shimoya

International Journal of Gynecological Cancer 18 ( 6 ) 1210 - 1214 2008.11

Language：English

The objective of this study was to retrospectively assess the efficacy and safety of combination chemotherapy of intraperitoneal (IP) carboplatin and intravenous (IV) paclitaxel in suboptimally debulked ovarian cancer. Between March 1998 and March 2006, 44 patients with histologically confirmed epithelial ovarian carcinoma or peritoneal carcinoma with a residual mass greater than 1 cm received combination chemotherapy of IV paclitaxel and IP carboplatin. Administration of IV paclitaxel at 175 mg/m2 immediately followed by IP carboplatin at an area under the curve of 6 was scheduled every 3 weeks for at least six cycles. The diagnosis and stage were ovarian carcinoma stage II in 8, III in 25, and IV in 6 cases, and peritoneal carcinoma stage III in 5 cases. Eighty-three percent of patients completed more than six cycles of chemotherapy. The incidences of grade 3/4 hematologic toxicities were 41 (93%) for neutrocytopenia, 10 (41%) for thrombocytopenia, and 18 (23%) for anemia. Observed grade 3/4 nonhematologic toxicities were 1 (2%) for allergy, 1 (2%) for fatigue, 1 (2%) for vomiting, 1 (2%) for liver dysfunction, and 4 (9%) for peripheral neuropathy. Two patients (5%) encountered catheter problems (one obstruction and one infection). Overall response rate was 80% (16 complete response, 19 partial response, 3 stable disease, and 6 progressive disease). Median progression-free survival and overall survival were 24 and 31 months, respectively. Combination chemotherapy of IP carboplatin and IV paclitaxel is effective and safe in suboptimally debulked ovarian cancer, and further evaluation is warranted. © 2008, Copyright the Authors.

DOI： 10.1111/j.1525-1438.2008.01192.x

Scopus

PubMed

researchmap

腹腔内化学療法 (特集婦人科がん診療のリスクマネージメント) -- (化学療法の問題点)

後藤友子, 長尾昌二, 藤原恵一

産婦人科の実際 57 ( 11 ) 1853 - 1856 2008.10

Conservative surgery for ovarian cancer

97 ( 2 ) 149 - 156 2008.8

Carboplatin dosing in obese women with ovarian cancer: A Gynecologic Oncology Group study International journal

Jason D. Wright, Chunqiao Tian, David G. Mutch, Thomas J. Herzog, Shoji Nagao, Keiichi Fujiwara, Matthew A. Powell

GYNECOLOGIC ONCOLOGY 109 ( 3 ) 353 - 358 2008.6

Language：English Publisher：ACADEMIC PRESS INC ELSEVIER SCIENCE

Background. Carboplatin dosing for gynecologic malignancies is traditionally based on the Jelliffe formula that lacks dose adjustment for weight. Obese women may therefore receive a sub-therapeutic carboplatin dose. This study assessed the association between BM I and outcome for ovarian cancer patients treated with carboplatin-based chemotherapy.
Methods. An analysis of patients treated with carboplatin and paclitaxel on Gynecologic Oncology Group (GOG) protocol 158 was perfonned. The dose of carboplatin for each patient was based on an area under the curve of 7.5 and a glomerular filtration rate (GFR) derived from the Jelliffe formula which is derived from age and serum creatinine. Patients were stratified based on body mass index (BMI).
Results. A total of 387 patients were included in the analysis. The patients were stratified into three groups: normal weight (BMI < 25.0, 50%), overweight (BMI 25-29.9, 32%) and obese (BMI >= 30.0, 18%). Compared to pretreatment values, the obese patients had a lower relative decrease in their platelet counts (- 25% for BMI >= 30 vs. - 6 1% for BMI < 25) (p = 0.01). Similar trends were noted for relative changes in hemoglobin (p = 0.006) and hematocrit (p = 0.002). Dose reductions were required in 34% of normal weight compared to 2 1% of the obese women (p = 0.004). There was a trend toward increased risk for disease progression in women with a BMI >= 30 (RR: 1.25, 95% CI: 0.93-1.69, p = 0. 14).
Conclusion. Obese ovarian cancer patients treated with carboplatin experience substantially less toxicity than normal weight women. The lower toxicity suggests that obese patients may be receiving a substandard drug dose. (c) 2008 Elsevier Inc. All rights reserved.

DOI： 10.1016/j.ygyno.2008.02.023

Web of Science

PubMed

researchmap

上皮性卵巣がんに対するcarboplatin腹腔内投与およびpaclitaxel静脈内点滴投与の有用性

長尾昌二, 大石理恵, 塚本有佳子, 中西美恵, 岩佐紀宏, 清水基弘, 後藤友子, 藤原恵一, 下屋浩一郎

癌の臨床 54 ( 5 ) 1 - 7 2008.5

Combination chemotherapy of intraperitoneal carboplatin and intravenous taxane in advanced endometrial cancer: A pilot study

S. Nagao, R. Oishi, Y. Tsukamoto, Y. Nakanishi, N. Iwasa, M. Shimizu, T. Goto, K. Fujiwara

JOURNAL OF CLINICAL ONCOLOGY 26 ( 15 ) 2008.5

【婦人科関連抗がん剤の必修知識】分子標的治療薬トラスツズマブ/ベバシズマブ(解説/特集)

藤原恵一, 清水基弘, 岩佐紀宏, 大石理恵, 中西美恵, 後藤友子, 長尾昌

産科と婦人科 75 ( 3 ) 347 - 351 2008.2

Combination chemotherapy of intraperitoneal carboplatin and intravenous paclitaxel in epithelial ovarian cancer

Japanese journal of cancer clinics 54 ( 5 ) 343 - 349 2008

Feasibility of extraperitoneal laparoscopic para-aortic and common iliac lymphadenectomy

Shoji Nagao, Keiichi Fujiwara

GYNECOLOGIC ONCOLOGY 106 ( 2 ) 435 - 435 2007.8

【婦人科がんに対する新しい治療法の導入】分子標的治療の最新情報と展望(解説/特集)

藤原恵一, 清水基弘, 尾, 後藤友子, 菊池真理子, 伊藤百合子, 三木明徳

産婦人科の実際 56 ( 4 ) 539 - 545 2007.5

【卵巣がん患者の治療をめぐって】新しい薬剤の開発とその展望(解説/特集)

藤原恵一, 長尾昌二, 清水基弘

臨床腫瘍プラクティス 3 ( 2 ) 178 - 182 2007.5

女性外来診療マニュアル】症状・症候から診断・治療へ婦人科編外陰・腟腫瘍、類腫

藤原恵一, 清水基弘, 後藤友子, 三木明徳, 長尾昌

産婦人科治療 686 - 692 2007.4

卵巣癌に対する妊よう性保存手術

長尾昌二, 藤原恵一, 清水基弘

産婦人科治療 94 ( 3 ) 299 - 304 2007.3

Intraperitoneal carboplatin-based chemotherapy for ovarian cancer

Keiichi Fujiwara, Shoji Nagao, Tomoko Goto, Motohiro Shimizu, Norihiro Iwasa

CANCER INVESTIGATION 25 24 - 25 2007

P1-69 埼玉県西部地区における子宮頸部上皮内新生物症例に検出されたHPV型分析(Group5 子宮頸部腫瘍5,一般演題,第59回日本産科婦人科学会学術講演会)

武居智信, 藤村正樹, 清水基弘, 長尾昌二, 三木明徳, 藤原恵一, 石原理

日本産科婦人科學會雜誌 59 ( 2 ) 371 - 371 2007

P2-128 1cm以上の残存腫瘍を有する上皮性卵巣癌患者に対するパクリタキセル静脈内点滴投与およびカルボプラチン腹腔内(IP)投与(TC療法)の検討(Group118 卵巣腫瘍8,一般演題,第59回日本産科婦人科学会学術講演会)

長尾昌二, 藤原恵一, 田丸俊輔, 高橋幸子, 伊藤百合子, 清水基弘, 三木明徳, 藤村正樹, 石原理, 前畑賢一郎, 下屋浩一郎

日本産科婦人科學會雜誌 59 ( 2 ) 606 - 606 2007

Feasibility of extraperitoneal laparoscopic para-aortic and common iliac lymphadenectomy International journal

Shoji Nagao, Keiichi Fujiwara, Reina Kagawa, Yoshiaki Kozuka, Takashi Oda, Kenichiro Maehata, Hiroyasu Ishikawa, Hirofumi Koike, Ichiro Kohno

GYNECOLOGIC ONCOLOGY 103 ( 2 ) 732 - 735 2006.11

Language：English Publisher：ACADEMIC PRESS INC ELSEVIER SCIENCE

Objective. The aim of this study is to evaluate the feasibility of extraperitoneal laparoscopic para-aortic and common iliac lymphadenectomy for cervical and endometrial carcinoma.
Methods. Seventy-six patients underwent extraperitoneal laparoscopic para-aortic and common iliac lymphadenectomy between February 1999 and September 2005. The lymph nodes dissected with the laparoscopic procedure included the inframesenteric para-aortic lymph nodes, the sacral lymph nodes, and the bilateral common iliac lymph nodes. The extraperitoneal laparoscopic operation was performed with pelvic open surgery using Lap Disc to ensure the safety of patients.
Results. The number of patients with cervical and endometrial carcinoma was 36 and 40, respectively. The median age of patients was 51 years (range 24-75 years). Conversion to open surgery was necessary in 8 patients. These include 3 patients who encountered blood loss of 400, 136 and 128 ml; 2 extremely obese women; and 3 patients who had peritoneal tears causing CO2 gas leakage. Among the remaining 68 patients, the median operating time for extraperitoneal laparoscopic para-aortic and common iliac lymphadenectomy was 75 min (range 45-145 min), and the median estimated blood loss was 5 ml (range 5-138 ml). The median total number of resected nodes was 14 (range 2-31), and 4 patients had lymph node metastasis. No patient encountered postoperative complications attributable to extraperitoneal laparoscopic para-aortic and common iliac lymphadenectomy.
Conclusions. Extraperitoneal laparoscopic para-aortic and common iliac lymphadenectomy with pelvic open surgery using Lap Disc is a feasible procedure, particularly in the surgeons learning phase. (c) 2006 Elsevier Inc. All rights reserved.

DOI： 10.1016/j.ygyno.2006.04.026

Web of Science

PubMed

researchmap

Feasibility of extraperitoneal laparoscopic para-aortic and common iliac lymphadenectomy

Shoji Nagao, Keiichi Fujiwara, Reina Kagawa, Yoshiaki Kozuka, Takashi Oda, Kenichiro Maehata, Hiroyasu Ishikawa, Hirofumi Koike, Ichiro Kohno

GYNECOLOGIC ONCOLOGY 103 ( 2 ) 732 - 735 2006.11

Language：English Publisher：ACADEMIC PRESS INC ELSEVIER SCIENCE

DOI： 10.1016/j.ygyno.2006.04.026

Web of Science

researchmap

婦人科癌診療の新たな潮流卵巣癌に対する腹腔内化学療法の再評価

藤原恵一, 長尾昌二

産科と婦人科 9 ( 19 ) 1091 - 7 2006.9

Hormonal function after ovarian transposition to the abdominal subcutaneous fat tissue

S. Nagao, K. Fujiwara, H. Ishikawa, T. Oda, K. Tanaka, E. Aotani, I. Kohno

International Journal of Gynecological Cancer 16 ( 1 ) 121 - 124 2006.1

Language：English

We previously reported a new technique for ovarian transposition to the abdominal subcutaneous fat tissue (OTAFT) following hysterectomy. The purpose of this study is to assess the hormonal function after OTAFT. From 1993 to 2000, OTAFT was performed in 27 patients (group A). Forty-two women underwent hysterectomy and retained ovaries without transposition (group B). In 19 cases, bilateral oophorectomy with hysterectomy was performed, and they received a hormone replacement therapy (HRT) (group C). Serum follicle-stimulating hormone (FSH) level of patients was monitored every 2-12 months, and the time of menopause (defined as FSH &gt
40 mIU/mL two times consecutively) was determined in groups A and B. After a median follow-up of 65 months, cumulative ovarian survival did not show significant difference between group A and group B (HR = 0.52, 95% CI = 0.17-1.16
P= 0.10). In patients who were 40 years old or younger, ovarian function declined significantly in group A compared to group B (HR = 0.29, 95% CI = 0.02-0.91
P= 0.04). However, FSH level of postmenopausal patients in group A was not different from FSH level of patients in group C, but FSH level of postmenopausal patients in group B was significantly higher than FSH level of patients in group C (P= 0.002). Although the procedure of OTAFT may somewhat affect the ovarian function, the transposed ovary in postmenopausal women presumably still secrete a small amount of estrogen which is equivalent to an estrogen level by HRT. © 2006, IGCS.

DOI： 10.1111/j.1525-1438.2006.00280.x

Scopus

PubMed

researchmap

P1-39 長期経過観察を行ったCIN1(cervical intraepithelial lesion 1)症例における予後解析 : 高リスク型Human Papillomavirus(HPV)感染とHPV-DNAタイプ別の検討(Group 5 子宮頸部腫瘍V,一般演題,講演要旨,第58回日本産科婦人科学会学術講演会)

小田隆司, 藤原恵一, 小塚良哲, 香川玲奈, 長尾昌二, 前畑賢一郎, 石川博康, 小池浩文, 河野一郎

日本産科婦人科學會雜誌 58 ( 2 ) 383 - 383 2006

P2-139 後腹膜鏡下傍大動脈リンパ節生検のFeasibility Study(Group 131 悪性腫瘍全般I,一般演題,講演要旨,第58回日本産科婦人科学会学術講演会)

長尾昌二, 香川玲奈, 小塚良哲, 小田隆司, 前畑賢一郎, 石川博康, 小池浩文, 藤原恵一, 河野一郎

日本産科婦人科學會雜誌 58 ( 2 ) 638 - 638 2006

Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin - A Sankai Gynecology Study Group (SGSG) study

Y Miyagi, K Fujiwara, J Kigawa, H Itamochi, S Nagao, E Aotani, N Terakawa, Kohno, I

GYNECOLOGIC ONCOLOGY 99 ( 3 ) 591 - 596 2005.12

Language：English Publisher：ACADEMIC PRESS INC ELSEVIER SCIENCE

Objective. To clarify the pharmacological advantage of carboplatin-based intraperitoneal chemotherapy using the three-compartment mathematical model. Methods. Eleven consecutive patients in one institution underwent intraperitoneal administration of carboplatin, and 11 consecutive patients in another institution received intravenous administration. Carboplatin (AUC = 6 mg x min/ml) was diluted in 500 ml 5% glucose and administered either as an intraperitoneal bolus infusion or intravenous drip infusion during I h. Patients undergoing intravenous injection also received an infusion of 500 ml 5% glucose to obtain intraperitoneal samples. Intraperitoneal fluid and blood samples were obtained, immediately and 1, 2, 4, 8 12, and 24 h after administration. The mathematical model consisting of a three-compartment model was applied to analyze the pharmacokinetics. The model was created with simultaneous differential equations and was solved by the Runge-Kutta method. Results. The rate constants of platinum diffusion from the peritoneal cavity to serum, serum to peritoneal cavity, serum to peripheral space, peripheral space to serum, and elimination were 0.94 +/- 0.79 (mean +/- SD), 1.28 +/- 2.50, 16.50 +/- 9.26, 0.99 +/- 0.62, and 4.14 +/- 1.45 (h(-1)), respectively. When the theoretical pharmacological concentration of platinum was calculated using this mathematical model, 24-h platinum AUC in the serum was exactly the same regardless of intraperitoneal or intravenous administration of carboplatin. However, the 24-h platinum AUC in the peritoneal cavity was approximately 17 times higher when carboplatin was administered by the intraperitoneal route. Conclusion. The present pharmacological analysis suggests that intraperitoneal infusion of carboplatin is feasible not only as an intraperitoneal regional therapy but also as a more reasonable route for systemic chemotherapy. (c) 2005 Elsevier Inc. All rights reserved.

DOI： 10.1016/j.ygyno.2005.06.055

Web of Science

researchmap

Y Miyagi, K Fujiwara, J Kigawa, H Itamochi, S Nagao, E Aotani, N Terakawa, Kohno, I

GYNECOLOGIC ONCOLOGY 99 ( 3 ) 591 - 596 2005.12

Language：English Publisher：ACADEMIC PRESS INC ELSEVIER SCIENCE

DOI： 10.1016/j.ygyno.2005.06.055

Web of Science

PubMed

researchmap

Difference of carboplatin clearance estimated by the Cockroft-Gault, Jelliffe, Modified-Jelliffe, Wright or Chatelut formula

S Nagao, K Fujiwara, N Imafuku, R Kagawa, Y Kozuka, T Oda, K Maehata, H Ishikawa, H Koike, E Aotani, Kohno, I

GYNECOLOGIC ONCOLOGY 99 ( 2 ) 327 - 333 2005.11

Language：English Publisher：ACADEMIC PRESS INC ELSEVIER SCIENCE

Objective. Although the Calvert Formula is the standard method to calculate the dose of carboplatin, there is no consensus how to determine the glomerular filtration rate (GFR) without Using [Cr-51]-ethylenediamine tetraacetic acid (Cr-51-EDTA). Creatinine clearance (Ccr), calculated using the Cockroft-Gault, Jelliffe, Modified-Jelliffe or Wright formulae, has been used as a substitute for the GFR. In addition to these four formulae, the Chatelut formula has been proposed as a way to calculate carboplatin clearance. Among these formulae, Jelliffe formula does not include body surface area (BSA) or body weight, it to adjust the body size and thus may have greater bias than the other four formulae ill estimating carboplatin clearance. The Purpose of this Study is to evaluate if these five formulae could equally estimate the carboplatin clearance.
Methods. Carboplatin clearance was estimated in 253 patients with gynecologic cancer who received carboplatin-based chemotherapy between January 1996 and August 2004. Ccr was estimated using the Cockroft-Gault, Jelliffe, Modified-Jelliffie or Wright formulae. Carboplatin clearance was also calculated directly by using the Chatelut formula. The five estimations of carboplatin clearance were compared with each other using the post-hoc Wilcoxon signed rank test. The median percent en-or (MPE) and the median absolute percent error (MAPE) were evaluated by comparing carboplatin clearance. The relationships between BSA and ratios of estimated carboplatin clearance (Jelliffe/Cockroft-Gault, Jelliffe/Modified-Jelliffe, Jelliffe/Wright, Jelliffe/Chatelut) were evaluated by using simple regression.
Results. The estimated carboplatin clearances were: Cockroft-Gault formula, 109.8 +/- 28.4; Jelliffe formula, 128.5 +/- 28.2; Modified-Jelliffe formula, 110.8 +/- 25.7; Wright formula, 112.2 +/- 24.3; Chatelut formula, 114.1 +/- 33.0. A statistically significant difference was observed between carboplatin clearance Calculated using Jelliffe formula and that given by each of the other four formulae. Comparing the results of the Cockroft-Gault formula with the Jellife, Modified-Jelliffe, Wright and Chatelut formulae yielded MPEs of +19%, +2%, +3% and +3% and MAPEs of 27%, 5%, 6% and 6%, respectively. There was a significant correlation between BSA and ratio of estimated carboplatin clearance (Jellife/Cockroft-Gault, Jelliffe/Modified-Jellife, Jelliffe/Wright, Jelliffe/Chatelut), with Pearson correlation coefficients of 0.928, 0.847, 0.965 and 0.839 respectively. As the BSA of patient became smaller, the differences between the carboplatin clearance calculated by the Jelliffe formula from other four formulas became larger.
Conclusions. Estimates of carboplatin clearance calculated by the Jelliffe formula tend to have greater positive bias compared to the other four formulae, particularly when the BSA of the patient is small. Ill order to conduct collaborative international Studies, it may be necessary to standardize the formula used to estimate carboplatin clearance to perforin international collaboration Studies. (c) 2005 Elsevier Inc. All rights reserved.

DOI： 10.1016/j.ygyno.2005.06.003

Web of Science

researchmap

Difference of carboplatin clearance estimated by the Cockroft-Gault, Jelliffe, Modified-Jelliffe, Wright or Chatelut formula International journal

S Nagao, K Fujiwara, N Imafuku, R Kagawa, Y Kozuka, T Oda, K Maehata, H Ishikawa, H Koike, E Aotani, Kohno, I

GYNECOLOGIC ONCOLOGY 99 ( 2 ) 327 - 333 2005.11

Language：English Publisher：ACADEMIC PRESS INC ELSEVIER SCIENCE

DOI： 10.1016/j.ygyno.2005.06.003

Web of Science

PubMed

researchmap

Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study International journal

S Nagao, K Fujiwara, T Oda, H Ishikawa, H Koike, H Tanaka, Kohno, I

GYNECOLOGIC ONCOLOGY 96 ( 3 ) 805 - 809 2005.3

Language：English Publisher：ACADEMIC PRESS INC ELSEVIER SCIENCE

Objectives. This is a pilot study for a future trial to assess the efficacy and safety of combination chemotherapy with docetaxel and carboplatin in advanced or recurrent uterine cervix cancer.
Methods. The patients eligible for this study had histologically confirmed, advanced (stage IB2-IV) or recurrent uterine cervix cancer. Eligible patients had measurable lesions and must have sufficient bone marrow, renal, and liver functions. Docetaxel was administered intravenously (IV) at 60 mg/m(2) followed by IV carboplatin administration based on AUC = 6. Chemotherapy was repeated in 1-6 courses depending on the purpose of the therapy. The response was evaluated based on RECIST criteria. The toxicity grade was determined by NCI-CTC version 2.
Results. During January 2001 and April 2004, 17 patients were entered in this study. The distribution of stage was IB2, 3; IIB, 8; IIIB, 3; IVB, 1; recurrent, 2. There were 9 squamous cell carcinomas, 6 adenocarcinomas, 1 adenosquamous cell carcinoma, and 1 small cell carcinoma. The overall response rate was 76% (2 CR, 11 PR, and 4 SD). No progression of disease was observed. All 5 adenocarcinoma patients in the neoadjuvant chemotherapy group responded including 1 pathological CR. The incidences of grade 3/4 toxicities were 76% for neutrocytopenia, 12% for thrombocytopenia, and 6% for anemia. No grade 3/4 neurotoxicity was observed.
Conclusions. The combination of docetaxel and carboplatin is an effective and safe treatment for uterine cervix cancer. Further evaluation particularly targeted on cervical adenocarcinoma is warranted. (c) 2004 Elsevier Inc. All rights reserved.

DOI： 10.1016/j.ygyno.2004.11.044

Web of Science

PubMed

researchmap

Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study

S Nagao, K Fujiwara, T Oda, H Ishikawa, H Koike, H Tanaka, Kohno, I

GYNECOLOGIC ONCOLOGY 96 ( 3 ) 805 - 809 2005.3

Language：English Publisher：ACADEMIC PRESS INC ELSEVIER SCIENCE

DOI： 10.1016/j.ygyno.2004.11.044

Web of Science

researchmap

高危険群ヒトパピローマウイルス (HPV) 感染を伴う子宮頸部上皮内腫瘍 (CIN) の取り扱いに関する研究(子宮頸部悪性腫瘍IV, 第57回日本産科婦人科学会学術講演会)